Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 24,100 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 24,100 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $21.10, for a total value of $508,510.00. Following the completion of the transaction, the director directly owned 1,081,044 shares of the company’s stock, valued at $22,810,028.40. This trade represents a 2.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Stock Up 1.6%

DYN stock opened at $20.94 on Friday. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a twelve month low of $8.06 and a twelve month high of $25.00. The company’s 50 day moving average is $18.45 and its two-hundred day moving average is $18.11. The stock has a market cap of $3.46 billion, a P/E ratio of -6.50 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the firm posted ($1.05) earnings per share. Research analysts expect that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC lifted its position in Dyne Therapeutics by 34.2% in the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after purchasing an additional 1,189,895 shares during the period. Bank of America Corp DE increased its position in Dyne Therapeutics by 63.5% during the 1st quarter. Bank of America Corp DE now owns 1,443,313 shares of the company’s stock worth $26,167,000 after purchasing an additional 560,391 shares during the period. California State Teachers Retirement System raised its stake in shares of Dyne Therapeutics by 15.6% during the 1st quarter. California State Teachers Retirement System now owns 139,663 shares of the company’s stock worth $2,532,000 after buying an additional 18,863 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Dyne Therapeutics by 267.6% in the 1st quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock valued at $1,236,000 after buying an additional 49,641 shares during the period. Finally, Rock Springs Capital Management LP boosted its stake in shares of Dyne Therapeutics by 6.5% in the first quarter. Rock Springs Capital Management LP now owns 972,198 shares of the company’s stock valued at $17,626,000 after buying an additional 59,243 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on DYN shares. HC Wainwright decreased their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research report on Friday. They set a “buy” rating on the stock. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Finally, Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.